Introduction: Gaucher disease type 3 (GD3) is a genetic, progressive lysosomal storage disorder characterized by visceral manifestations and chronic neurologic symptoms (e.g., horizontal ophthalmoplegia/supranuclear gaze palsy, ataxia, dystonia). The investigational agent venglustat is being studied in combination with imiglucerase as potential treatment for systemic and neuronopathic manifestations of GD3 in a single-arm, open-label, phase 2 trial (LEAP; N = 11). To understand perceived changes in GD3 symptoms from the perspectives of patients, caregivers, and clinicians, we conducted a qualitative case study of selected LEAP participants.

Methods: Four patients in LEAP (age range, 20-28 years), four of their caregivers, and three clinicians involved in LEAP were interviewed individually by moderators using semi-structured guides. Clinicians' perceptions were based on observation of interviewed patients and those in LEAP who were not interviewed, as well as information provided by other staff involved in LEAP, patients, and caregivers.

Results: Reported changes in GD3 symptoms varied among patients and among reporters. Only eye movement was spontaneously mentioned as improved by at least one patient, caregiver, and clinical expert. Symptom improvement also varied in terms of time to improvement. Within the first weeks, improvements were seen in understanding new information or complex instructions, remembering the weekday, eye movement, tremor, and seizures. Changes in alertness, engagement and responsiveness, memory, and concentration appeared after months or a year. Most caregivers and all clinical experts reported greater patient independence (e.g., increased ability to perform activities of daily living or travel independently during the trial) as a perceived treatment effect on a GD3 impact. For one patient who perceived benefits from venglustat therapy, pharmacokinetic analyses during LEAP found low to undetectable venglustat levels in their plasma and cerebrospinal fluid.

Conclusion: Outcomes from this study provide insights into GD3 symptoms and the early signaling of changes reported during venglustat therapy.

Trial Registration: ClinicalTrials.gov identifier, NCT02843035.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213771PMC
http://dx.doi.org/10.1007/s12325-024-02881-2DOI Listing

Publication Analysis

Top Keywords

gd3 symptoms
12
gaucher disease
8
disease type 3
8
leap
8
changes gd3
8
patients leap
8
involved leap
8
leap interviewed
8
eye movement
8
gd3
6

Similar Publications

Near-infrared (NIR)-emitting phosphors with high quantum efficiency and thermal stability are crucial to NIR pc-LEDs. Garnet-structured (GdLuCa)(AlSiCr)O ( = 0.01-0.

View Article and Find Full Text PDF

Organotropic Engineering of Luminescent Gold Nanoclusters for In Vivo Imaging of Lung Orthotopic Tumors.

ACS Nano

December 2024

MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China.

Gold nanoclusters (AuNCs) are emerging as promising functional probes for bioapplications. However, because of rapid renal clearance, it is a challenge to tailor their biofate and improve their disease-targeting ability in vivo. Herein, we report an efficient strategy to tailor their organotropic actions by rationally designing AuNC assemblies.

View Article and Find Full Text PDF

Rapid, Non-Invasive, Accurate Diagnosis and Efficient Clearance of Metastatic Lymph Nodes.

Angew Chem Int Ed Engl

November 2024

CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine andi-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.

Sentinel lymph node (SLN) biopsy is currently the standard procedure for clinical cancer diagnosis and treatment, but still faces the risks of false negatives and tumor metastasis, as well as time-consuming pathological evaluation procedure. Herein, we proposed a near-infrared-II (NIR-II, 1000-1700 nm) theranostic nanosystem (FLAGC) for rapid, non-invasive, accurate diagnosis and efficient clearance of metastatic lymph nodes in breast cancer. Initialized by chlorin e6 (Ce6), a pH-sensitive amphiphilic amino acid fluorenylmethoxycarbonyl-L-histidine (Fmoc-His) was assembled with Gd, luminol, and AgAuSe quantum dots (AAS QDs) to form FLAGC.

View Article and Find Full Text PDF

Water-Soluble Bimodal Magnetic-Fluorescent Radical Dendrimers as Potential MRI-FI Imaging Probes.

ACS Appl Mater Interfaces

November 2024

Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Campus UAB, E-08193 Bellaterra, Spain.

Dual or multimodal imaging probes have become potent tools for enhancing detection sensitivity and accuracy in disease diagnosis. In this context, we present a bimodal imaging dendrimer-based structure that integrates magnetic and fluorescent imaging probes for potential applications in magnetic resonance imaging and fluorescence imaging. It stands out as one of the rare examples where bimodal imaging probes use organic radicals as the magnetic source, despite their tendency to entirely quench fluorophore fluorescence.

View Article and Find Full Text PDF

Size dependent properties of Gd-free versus Gd-doped carbon dots for bioimaging application.

Sci Rep

November 2024

Light Matter Institute, UMR-5306, Claude Bernard University of Lyon/CNRS, Université de Lyon, 69622, Villeurbanne Cedex, France.

Gd- free carbon dots (CDs) were synthesized by one-step solvothermal method using urea, citric acid and 3-(trifluoromethyl)aniline as precursors. Additionally, Gd-doped CDs were prepared by incorporating gadolinium chloride (Gd ions) into the synthesis. Size selection of the purified CDs was achieved through filter membranes ranging from 3 kDa to 100 kDa.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!